Tongzhi Wu1, Tanya J Little2, Michelle J Bound2, Malcolm Borg3, Xiang Zhang2, Carolyn F Deacon4, Michael Horowitz2, Karen L Jones2, Christopher K Rayner2. 1. Discipline of Medicine, The University of Adelaide, Adelaide, Australia Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia tongzhi.wu@adelaide.edu.au. 2. Discipline of Medicine, The University of Adelaide, Adelaide, Australia Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia. 3. Discipline of Medicine, The University of Adelaide, Adelaide, Australia. 4. Department of Biomedical Science, University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVE: Nutrient "preloads" given before meals can attenuate postprandial glycemic excursions, at least partly by slowing gastric emptying and stimulating secretion of the incretins (i.e., glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]). This study was designed to evaluate whether a protein preload could improve the efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin to increase incretin concentrations, slow gastric emptying, and lower postprandial glycemia in type 2 diabetes. RESEARCH DESIGN AND METHODS: Twenty-two patients with type 2 diabetes treated withmetformin were studied on four occasions, receiving either 50 mg vildagliptin (VILD) or placebo (PLBO) on both the evening before and the morning of each study day. The latter dose was followed after 60 min by a preload drink containing either 25 g whey protein (WHEY) or control flavoring (CTRL), and after another 30 min by a (13)C-octanoate-labeled mashed potato meal. Plasma glucose and hormones, and gastric emptying, were evaluated. RESULTS: Compared with PLBO/CTRL, PLBO/WHEY reduced postprandial peak glycemia, increased plasma insulin, glucagon, and incretin hormones (total and intact), and slowed gastric emptying, whereas VILD/CTRL reduced both the peak and area under the curve for glucose, increased plasma intact incretins, and slowed gastric emptying but suppressed plasma glucagon and total incretins (P < 0.05 each). Compared with both PLBO/WHEY and VILD/CTRL, VILD/WHEY was associated with higher plasma intact GLP-1 and GIP, slower gastric emptying, and lower postprandial glycemia (P < 0.05 each). CONCLUSIONS: In metformin-treated type 2 diabetes, a protein preload has the capacity to enhance the efficacy of vildagliptin to slow gastric emptying, increase plasma intact incretins, and reduce postprandial glycemia.
RCT Entities:
OBJECTIVE: Nutrient "preloads" given before meals can attenuate postprandial glycemic excursions, at least partly by slowing gastric emptying and stimulating secretion of the incretins (i.e., glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]). This study was designed to evaluate whether a protein preload could improve the efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin to increase incretin concentrations, slow gastric emptying, and lower postprandial glycemia in type 2 diabetes. RESEARCH DESIGN AND METHODS: Twenty-two patients with type 2 diabetes treated with metformin were studied on four occasions, receiving either 50 mg vildagliptin (VILD) or placebo (PLBO) on both the evening before and the morning of each study day. The latter dose was followed after 60 min by a preload drink containing either 25 g whey protein (WHEY) or control flavoring (CTRL), and after another 30 min by a (13)C-octanoate-labeled mashed potato meal. Plasma glucose and hormones, and gastric emptying, were evaluated. RESULTS: Compared with PLBO/CTRL, PLBO/WHEY reduced postprandial peak glycemia, increased plasma insulin, glucagon, and incretin hormones (total and intact), and slowed gastric emptying, whereas VILD/CTRL reduced both the peak and area under the curve for glucose, increased plasma intact incretins, and slowed gastric emptying but suppressed plasma glucagon and total incretins (P < 0.05 each). Compared with both PLBO/WHEY and VILD/CTRL, VILD/WHEY was associated with higher plasma intact GLP-1 and GIP, slower gastric emptying, and lower postprandial glycemia (P < 0.05 each). CONCLUSIONS: In metformin-treated type 2 diabetes, a protein preload has the capacity to enhance the efficacy of vildagliptin to slow gastric emptying, increase plasma intact incretins, and reduce postprandial glycemia.
Authors: Étienne Myette-Côté; Hannah G Caldwell; Philip N Ainslie; Kieran Clarke; Jonathan P Little Journal: Am J Clin Nutr Date: 2019-12-01 Impact factor: 7.045
Authors: Michael Willmann; Irina Sadovnik; Gregor Eisenwort; Martin Entner; Tina Bernthaler; Gabriele Stefanzl; Emir Hadzijusufovic; Daniela Berger; Harald Herrmann; Gregor Hoermann; Peter Valent; Thomas Rülicke Journal: Exp Hematol Date: 2017-10-12 Impact factor: 3.084
Authors: Roberto Testa; Anna Rita Bonfigli; Francesco Prattichizzo; Lucia La Sala; Valeria De Nigris; Antonio Ceriello Journal: Nutrients Date: 2017-04-28 Impact factor: 5.717
Authors: Kieran Smith; Guy S Taylor; Dean M Allerton; Lise Hoej Brunsgaard; Kelly A Bowden Davies; Emma J Stevenson; Daniel J West Journal: Front Endocrinol (Lausanne) Date: 2021-06-18 Impact factor: 5.555